Theranos said it has secured $10 million in funding for its handheld device designed to wirelessly monitor adverse drug reactions. The device tests tiny blood samples using a biochip and sends an alert if overly-high drug concentrations or other warning signs are detected. Patients can log on to the company's Web site to view details of their current status. Physicians can check results online via the web. The company will initially focus on the oncology market. Theranos is based in Menlo Park, California and was founded by Elizabeth Holmes, an overachieving 22-year-old Stanford grad.
- read the article from Red Herring